www.nature.com/ejcn

ORIGINAL ARTICLE

The beneficial effects of aerobic and concurrent training on metabolic profile and body composition after detraining: a 1-year follow-up in postmenopausal women

FE Rossi^{1,2}, TA Diniz³, LM Neves⁴, ACS Fortaleza¹, J Gerosa-Neto^{1,2}, DS Inoue^{1,2}, C Buonani⁵, JM Cholewa⁶, FS Lira^{2,5} and IF Freitas Jr⁵

BACKGROUND/OBJECTIVES: Aerobic and concurrent training (CT, aerobic and strength training) improves body composition and metabolic profile; however, it is not known whether these positive outcomes acquired after aerobic or CT are maintained long term (≥ 6 months) after program interruption in postmenopausal women. This study investigated the changes in total and appendicular body composition, bone mineral density and metabolic profile following 16 weeks of aerobic or CT, and through 6 months and 1 year of detraining in postmenopausal women.

SUBJECTS/METHODS: In total, 60 postmenopausal women were divided into the following groups: aerobic (AT), aerobic plus strength training (CT) and control group (CG), and 31 participants were assessed for the 1 year follow-up. Body composition and bone mineral density were evaluated by dual-energy X-ray absorptiometry (DXA), and total cholesterol, high-density lipoprotein cholesterol, triacylglycerol, glucose, insulin, leptin, adiponectin and plasminogen activator inhibitor-1 (PAI-1) were assessed.

RESULTS: There were main effects of time for arm fat mass, arm lean mass and trunk lean mass (P < 0.05). There was a statistical difference between AT and CG for leg fat mass and percentage of fat (P < 0.05). After 6 months of detraining, leg lean mass decreased in relation to post-intervention, and there was a statistically significant interaction for total and appendicular lean mass (P < 0.05). There were differences between CT and CG in glucose and between AT and CG in glucose and triacylglycerol (P < 0.05). **CONCLUSIONS:** A duration of 16 weeks of aerobic or CT improved total and appendicular body composition and metabolic profile but after 6 months of detraining, leg lean mass returned to the values obtained pre-training in CT.

European Journal of Clinical Nutrition advance online publication, 25 January 2017; doi:10.1038/ejcn.2016.263

INTRODUCTION

The menopausal period results not only in lower estrogen hormone concentrations but also contributes to significant changes in body composition, increasing fat mass and central adiposity,¹ which is linked to the development of morbidities such as hypertension, type 2 diabetes mellitus, dyslipidemia and metabolic syndrome.² These morbidities increase the risk of cardiovascular diseases, such as atherosclerosis, which is the leading cause of death worldwide.³ Furthermore, physical inactivity can lead to decreased lean mass (LM), bone mass and muscular strength, which can result in the development of musculoskeletal diseases such as sarcopenia and osteoporosis, impaired locomotion, balance, increasing fragility, incidence of falls and consequently decrease the quality of life during daily activities.⁴

Several studies have assessed exercise interventions in an attempt to minimize the deleterious effects of the postmenopausal period. Aerobic exercise has demonstrated anti-inflammatory effects,⁵ improved cardiovascular fitness, oxidation of lipids in skeletal muscle and liver,⁶ and has been shown to induce significant improvements in the reduction/control of whole and

central adiposity,⁷ lipids and lipoproteins.⁸ On the other hand, strength training has anti-catabolic effects, increases the oxidation of carbohydrates in skeletal muscle and increases muscle anabolism.⁹ Therefore, the combination of aerobic plus strength training (concurrent training (CT)) is a promising option for increasing LM, decreasing total fat mass and trunk fat,^{10,11} and regulating the metabolic profile in postmenopausal women.¹²

Physical activity (PA) and exercise training improves body composition and metabolic profile in various populations, but to prevent lifestyle-related diseases, it is important not only to encourage people to start a training program but also to maintain adherence¹³ as adaptations that occur during training are reversible and often lost following detraining.¹⁴ Therefore, more research is needed to study training methods that induce longer lasting adaptations following the cessation of exercise training.

Mora-Rodriguez *et al.*¹⁵ investigated the time-course effects of 4 months of aerobic training (AT) and short-term detraining (1 month) in patients with metabolic syndrome and reported that high-density lipoprotein cholesterol (HDL-c) and VO2peak decreased to the values obtained after 1–2 months of training, whereas HOMA index and maximal fat oxidation returned to

¹Institute of Bioscience, São Paulo State University, Rio Claro, São Paulo, Brazil; ²Exercise and Immunometabolism Research Group, Department of Physical Education, São Paulo, State University (UNESP), Presidente Prudente, SP, Brazil; ³Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, São Paulo, Brazil; ⁴School of Physical Education and Sport, University of São Paulo (USP), São Paulo, Brazil; ⁵Department of Physical Education, São Paulo State University, Presidente Prudente, São Paulo, Brazil; ⁴School of Physical and ⁶Department of Kinesiology, Recreation, and Sport Studies, Coastal Carolina University, Conway, SC, USA. Correspondence: Professor FE Rossi, Exercise and Immunometabolism Research Group, Department of Physical Education, University Estadual Paulista (UNESP) "Júlio Mesquita Filho". Roberto Simonsen Street, No 305 – Education Center, Presidente Prudente, São Paulo 19060-900, Brazil.

E-mail: rossifabricio@yahoo.com.br

Received 16 April 2016; revised 21 September 2016; accepted 14 October 2016

pre-training values. Lo *et al.*¹⁶ compared body composition, body size and muscle strength after 24 weeks of strength or AT and 24 weeks of detraining in young men and concluded that resistance training maintained the gains in strength and LM for more prolonged periods compared with AT.

Therefore, it is not known whether these positive outcomes acquired after aerobic or CT are maintained for longer periods (≥ 6 months) after program interruption in postmenopausal women, or whether there are differences between AT and CT with regard to adaptation maintainability during detraining. We hypothesized that CT would be more efficient than AT in improving LM, fat mass, bone mass and metabolic profile by emphasizing both aerobic and strength training, and that the benefits would be maintained for a longer time (6 months to 1 year). Thus, the objectives of the present study were to investigate the changes in total and appendicular body composition and metabolic profile after 6 months and 1-year follow-up in relation to the corresponding values before and after aerobic or CT in postmenopausal women.

METHODS

Participants and study design

This controlled clinical trial study was carried out at the Science and Technology Department of the University Estadual Paulista (FCT/UNESP), Presidente Prudente campus – São Paulo, Brazil. This study was performed according to the guidelines of the Declaration of Helsinki. The project was approved by the Ethics Research Group of the University (Protocol 64/2011) and Brazilian registry of clinical trial (RBR-9CBP8S).

Evaluations were performed at baseline, post training and after 6 months and 1 year of detraining (follow-up) in all the groups and involved the following: screening for inclusion in the study (only baseline), metabolic profile measurements, body composition, three nonconsecutive 24-h dietary questionnaires and free-living PA assessment.

Participants were invited through television and newspaper advertising to participate in the study. The participants contacted the researchers by phone and an appointment was made in order to carry out a more detailed interview. All measurements were taken at the university laboratory. The inclusion criteria were as follows: (1) being in menopause (having had no menstrual cycle for one or more years) and FSH \geq 26.72 mUl/ml; (2) not taking medication for diabetes and/or dyslipidaemia; (3) not consuming tobacco or alcohol; (4) not having

participated in any systematic physical exercise for at least 6 months before the study; (5) not receiving hormone replacement therapy treatments; (6) not presenting any physical limitations or health problems that could prevent the completion of the assessments and exercise interventions; and (7) signing the consent form.

We performed a power analysis of this study based on the observation from a previous study that verified a reduction in trunk fat of 0.9 kg and s.d. of 0.6 after 16 weeks of AT and detraining in patients with metabolic syndrome.¹⁵ Our primary hypothesis was that this difference would be statistically significant as compared with the control group (CG) assessed at the similar time period, with a power (1-type II error) of 0.80 and a type I error of 0.05. Using PS software (ver 3.1.2, Dupont and Plummer, http:// biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize), it was estimated that we would need eight participants per group. Considering a dropout rate of 25–40%, we over-recruited the number of participants.

Out of a total of 113 women who participated in the first screening, only 60 women met all the inclusion criteria and agreed to participate in the study protocol. Participants were randomized into the following three study groups for 16 weeks of training: CT (n = 20), AT (n = 20) and a CG (n = 20) which maintained 16 weeks without participating in any regular PA. Simple randomization techniques were used for allocation, which ensures that trial participants have an equal chance of being allocated to a treatment group;¹⁷ furthermore, the investigator was blinded to the group allocation during the experiment and/or when assessing the outcome. During the 16 weeks of training, five women from each group dropped out of the study (a dropout rate of 25%) and were excluded from the final analysis. The reasons for dropouts included personal/family problems, unspecified reasons or the participants did not comply with over 80% of frequency during the training program. After the intervention participants were encouraged to maintain their habits, and the researchers contacted the participants by phone after 6 months and then 1 year after the end of training. After 6 months and 1 year follow-up, the participants were evaluated again: CT (n = 15), AT (n = 8) and CG (n = 8). The reasons for dropouts at this measurement time point included personal/family problems, unspecified reasons or the participants refused to come back for assessing (Figure 1).

PROCEDURES

Body composition, dietary intake and free-living physical activity assessment

Body weight was measured using an electronic scale (Filizola PL 50, Filizzola Ltda., São Paulo, Brazil), with a precision of 0.1 kg.




Figure 1. The trial profile of this study.

2

Height was measured on a fixed stadiometer of the Sanny brand, (Sanny brand, São Paulo, Brazil) with an accuracy of 0.1 cm and a length of 2.20 m. The participants remained barefoot, wearing light clothing and standing at the base of the stadiometer, positioning themselves with their backs to the machine, touching their shoulder blades, buttocks and heels to the equipment's vertical support. Total fat mass, total LM, trunk fat, trunk LM, leg LM (LLM), arm LM, total bone mineral content in kilograms, percentage of fat mass and bone mineral density (BMD in q/cm^2) were estimated using a dual-energy X-ray absorptiometry scanner, version 4.7 (General Electric Healthcare, Lunar DPX-NT; England). The appendicular body composition was estimated according to Bhupathiraju et al.¹⁸ The participants were positioned in a supine position and remained still throughout the examination. To calculate the technical error of measurement of the dual-energy X-ray absorptiometry, two whole-body evaluations were performed, by the same evaluator, on two consecutive days with 12 female subjects. From the results obtained the average error was estimated as follows: ± 0.05 kg for total body fat, ± 0.28 kg for total trunk fat, ± 0.37 kg for total lean body mass, ± 1.06 kg for LLM and \pm 0.14 kg for bone mineral content. The test-retest intraclass correlation coefficient of these procedure has been shown reliable for all variables measured in this study (ICC between 0.91 and 0.99).

Twenty-four hour daily dietary records were conducted via 3-day food diaries that consisted of one weekend day (Sunday) and two weekdays (Monday and Wednesday or Tuesday and Thursday) to best reflect typical intakes. Participants were instructed by a nutritionist as to how to complete the dietary questionnaires. Total intake for the three days was then averaged and represented in different moments during the intervention. Questionnaires were analyzed by the same nutritionist using the software NutWin version 1.5 (Programa de Apoio à Nutrição, Universidade Federal de São Paulo, São Paulo, Brazil, 2002).

PA was measured by accelerometers (ActiGraph GT3X. Pensacola. FL). The PA intensity was measured in 60-s epochs, which is related to low intensity and long duration patterns of PA.¹ Accelerometers were placed on the participant's waists using an elastic band. The participants used the equipment for 8 days (only seven were full days). Instructions for use were provided. The accelerometer had to be used all day during the hours that the participant remained awake and was only to be removed when there was contact with water (personal hygiene or water activities).²⁰ Specific software (The ActiLife5 Data Analysis Software by Actigraph, Pensacola, FL, USA) was used to analyze the data. We included only the full days of monitoring in the database. Sixty consecutive minutes of zero counts were considered to be periods that the individual was not wearing the accelerometer and days containing less than ten hours of monitoring were excluded from the analysis, as they had the power to increase variability. At the end, only the participants who had at least 5 full days of monitoring (including at least one weekend) were included in this analysis.

Blood samples

After an overnight fast (12 h), venous blood samples were collected to measure total fasting cholesterol (Chol; mg/dL), HDL-c (mg/dL), triacylglycerol (TAG; mg/dL) and glucose (mg/dL) using the colorimetric technique and dry chemicals, with equipment of the Johnson and Johnson brand, model Vitros 250. The Friedewald *et al.*²¹ formula was used to calculate low-density lipoprotein cholesterol concentration (LDL-c; mg/dL). Serum insulin (0–300 μ IU/ml), leptin (2000–31.25 ng/mL), adiponectin (4000–62.5 ug/mL) and plasminogen activator inhibitor-1 (PAI-1 = 20–0.3125 ng/ml) were quantified using enzyme-linked immunosorbent assay with a commercial Kit (RayBio Human ELISA Kit, Norcross, GA, United States) as per the manufacturer's

instructions. In addition, the homeostatic model assessmentinsulin resistance was calculated according to Lejskova *et al.*²²

Aerobic training procedures

The intensities of the AT were established according to the anaerobic threshold (LAN) determined by critical velocity protocol proposed by Wakayoshi et al.23 The studied group traveled three distances (400, 800 and 1200 m) on a running track on separate nonconsecutive days. The participants were instructed to cover the distance in the shortest possible time, which was recorded using a digital stopwatch (Polar Electro, model S810i, Finland).²⁴ The relationship between the distance (m) and the exercise time (s) was linearly adjusted and the critical velocity was assumed to be the slope of this model, which represented the intensity of the AT.^{23,24} The intensity of training was 100% of LAN for 50 min/day, three times per week (Monday, Wednesday and Friday) on a running track, including 10 min of warm-up and stretching at the end of the training session. After 4 weeks, the procedures were repeated to adjust the intensities. Participants were instructed to drink water and wear appropriate shoes and clothing during training.

Concurrent training procedures

CT was performed for ~60 min per day with 30 min of strength training and 30 min of AT, three times per week (Monday, Wednesday and Friday). The intensity of training was 100% of LAN and it was established according to the anaerobic threshold, determined by critical velocity protocol, similarly described above for AT. The exercises used in the program were as follows: 45° leg press, leg extension, leg curl, bench press, seated row, arm curl, triceps extension, side lateral raises with dumbbells and abdominal exercises. The strength training program consisted of four progressive phases (phase 1 (1st to 4th week, 3 sets of 15 repetitions); phase 2 (5–8th week, 3 sets of 12 repetitions); phase 3 (9–12th week, 3 sets of 10 repetitions) and phase 4 (13–16th week, 3 sets of 8 repetitions)), 60–90 s of rest was provided between sets and exercises.

The intensity of the strength training was controlled through the zone of repetition maximum (RM). The sets were executed until momentary exhaustion, (that is, when the participants performed the training with repetitions varying from 12 to 15 RM, they were always encouraged to execute at least 12 and no more than 15 RM).²⁵ In the case of the participants executing more repetitions, the load was increased in order to keep within the training zone.²⁵

Statistical analysis

The Levene test was used to analyze the data set homogeneity. and a one-way analysis of variance was used to identify similarity of groups at baseline. Student's t-test for independent samples was used for insulin analysis because only two groups were analyzed in this variable. For analysis of the PA level at baseline we utilized Kruskal-Wallis test, as the data presented nonparametric distribution. Linear mixed models were used to compare the aerobic, CT and CG on metabolic profile and body composition. When a significant difference in group or interaction was observed, a Tukey's post hoc test was conducted. For all measured variables, the estimated sphericity was verified according to Mauchly's W test and the Greenhouse-Geisser correction was used when necessary. In addition, body composition and metabolic profile were controlled for free-living PA and energy intake after 6 months and 1 year follow-up. Finally, 'mean differences' (1-year follow-up value minus post-intervention value) were calculated and linear regression between fat mass, TFM, LM and metabolic profile were conducted to verify the association between variables after 1 year follow-up. The effect size (ES) was

calculated as the mean pre–post change divided by the pooled pretest standard deviation, and statistical significance was set *a priori* at P < 0.05. The data were analyzed using the Statistical Package for Social Sciences 17.0 (*SPSS* Inc. Chicago, IL, USA).

RESULTS

Table 1 presents the mean values for body weight, total and appendicular body composition, and metabolic profile at baseline in the three groups studied. There were no statistically significant differences between groups at baseline for all variables investigated.

In relation to the free-living PA presented in counts per minute, there were no differences at the baseline (P = 0.116) and across time in all groups (P = 0.224), and there were no observed differences between groups (P = 0.203) or interaction (time x group, P = 0.795; Figure 2a).

Regarding dietary intake (expressed in kcal), there were no differences at baseline (P = 0.072), across time (P = 0.169), between groups (P = 0.105), or interaction (time x group, P = 0.082; Figure 2b).

Table 2 presents the comparison in total and appendicular fat mass, and body weight after 6 months and 1 year follow-up. Table 3 displays the comparison in total and appendicular fat-free mass and BMD after 6 months and 1 year follow-up.

For total and appendicular fat mass, there were statistically significant differences between CT and AT for leg (P = 0.017, ES = 0.20) and percentage of fat (P = 0.011, ES = 0.22), but there were no significant differences between groups for total fat mass (P = 0.069, ES = 0.14). There was a main effect of time for arm (P = 0.019, ES = 0.10); however, the Tukey's *Post hoc* was not

Variables	CG (n=20)	<i>AT</i> (n = 20)	<i>CT</i> (n = 20)	P-valu
Age (years)	62.8±5.9	60.6 ± 7.9	62.4 ± 5.1	0.622
FSH (mUI/ml)	56.2 ± 12.6	69.0 ± 23.9	71.8 ± 26.7	0.153
Height (cm)	154.9 ± 7.7	156.6 ± 5.7	157.8 ± 6.1	0.437
Weight (Kg)	64.0 ± 11.3	65.3 <u>+</u> 9.3	60.0 ± 7.6	0.236
Fat mass				
Arm (Kg)	2.5 ± 0.9	2.6 ± 1.0	2.1 ± 0.7	0.147
Leg (Kg)	9.3 ± 3.5	10.0 ± 3.0	8.3 ± 1.7	0.126
Trunk (Kg)	15.2 ± 4.6	14.9 ± 3.3	12.6 ± 3.0	0.061
Total fat mass (Kg)	27.9 ± 8.7	28.5 ± 7.1	24.0 ± 5.0	0.073
Percentage of fat (%)	42.8 ± 6.6	43.1 ± 5.7	39.8 ± 4.1	0.065
LM				
Arms (Kg)	3.9 ± 0.6	4.0 ± 0.5	3.8 ± 0.6	0.706
Legs (Kg)	10.9 ± 1.4	11.3 ± 1.1	11.0 ± 1.3	0.773
Trunk (Kg)	16.2 ± 1.6	15.8 ± 1.6	15.8 ± 1.9	0.898
Total LM (Kg)	34.0 ± 3.4	34.4 ± 3.1	33.7 ± 3.7	0.967
Bone mass				
Total BMC (Kg)	2.0 ± 0.4	2.4 ± 0.4	2.1 ± 0.2	0.110
BMD (g/cm ²)	1.071 ± 0.1	1.148 ± 0.1	1.066 ± 0.9	0.18
Metabolic profile				
Glucose (mg/dL)	99.9 ± 36.0	88.6 ± 13.2	89.6 ± 13.6	0.364
TAG (mg/dL)	154.5 ± 62.8	101.3 ± 34.7	130.5 ± 57.1	0.088
Chol (mg/dL)	207.5 ± 34.8	200.9 ± 41.4	207.0 ± 30.0	0.872
HDL-c (mg/dL)	54.3 ± 13.9	54.7 ± 10.5	53.6 ± 16.1	0.978
LDL-c (mg/dL)	122.4 ± 36.3	126.0 ± 36.2	127.3 ± 27.8	0.923
Insulin (µIU/mI) ^a	-	6.4 ± 2.5	4.3 ± 1.9	0.064
Leptin (ng/mL)	130.6 ± 60.0	107.9 ± 48.1	71.2 ± 44.0	0.216
Adiponectin (ug/mL)	12.3 ± 0.2	11.4 ± 1.9	11.4 <u>+</u> 2.7	0.885
PAI-1 (ng/mL)	15.0 ± 5.2	12.6 ± 5.3	20.9 ± 23.0	0.662

bone mineral density (g/cm²); CG, control group; chol, total cholesterol; CT, concurrent training; FSH, follicle-stimulating hormone (mUI/mI); HDL-c, high-density lipoprotein cholesterol; LDL-c,low-density lipoprotein cholesterol concentration; PAI-1, Plasminogen activator inhibitor-1; TAG, triacylglycerol. ^aStudent test for independent sample was performed. significant. There were no statistical interactions as displayed in Table 2 (P > 0.05). When controlled for free-living PA and energy intake, the significant differences for total and appendicular fat mass after 6 months and 1 year follow-up were maintained (P < 0.05).

For total and appendicular LM, there was a main effect of time for arm (P = 0.002, ES = 0.13). The *post hoc* test showed to a statistically significant difference after 1-year follow-up compared with baseline (P = 0.002) and after 6 months of detraining (P = 0.005). LLM decreased significantly after 6 months of detraining in relation to post-intervention (P = 0.030, ES = 0.081), and trunk LM increased after training in relation to the baseline (P = 0.030, ES = 0.074). There were statistically significant interactions for arm, leg and total LM (Table 3). In addition, when controlling for free-living PA and energy intake, the significant differences in total and appendicular LM after 6 months and 1 year follow-up were maintained (P < 0.05). There were no statistically significant differences between groups (P > 0.05), and there were no statistically significant differences in bone mass content and BMD.

With regard to the metabolic profile, there were statistically significant differences between groups for glucose (P = 0.047, ES = 0.11). *Post hoc* analysis showed significant differences between CT and CG (P = 0.016) and AT and CG (P = 0.038) but no difference between CT and AT (P = 0.955). For TAG, there was a statistically significant difference only between AT and CG (P = 0.011, ES = 0.084), and there were no main effects of time for both variables (P > 0.05). However, when we adjusted for energy intake after 6 months and 1 year follow-up, there were no significant differences between group for glucose and TAG (P > 0.05). There were no main effects of time or statistically




Figure 2. Free-living PA presented in counts per minute/week (a) and dietary intake (expressed in kcal/week) (b).

4

Exercise,	metabolic	profile	and 1	year	follow-up
FE Rossi	et al				

after 6 months and 1-y follow-up

Variables

5

'ariables	CG (n = 8)	AT (n = 8)	<i>CT (</i> n = 15)	Time x group
at mass				
Arm (Kg)				
Pre	2.1 ± 0.8	2.8 ± 0.9	2.2 ± 0.7	0.790
Post	2.0 ± 0.7	2.6 ± 0.8	2.2 ± 0.8	
After 6-months	2.0 ± 0.7	2.6 ± 0.8	2.1 ± 0.8	
After 1-y	$2.0\pm~0.8$	2.5 ± 0.8	2.1 ± 0.8	
Leg (Kg)				
Pre	8.2 ± 2.3	10.7 ± 2.3	8.2 ± 1.7	0.572 ^a
Post	8.2 ± 2.4	10.5 ± 2.2	8.1 ± 2.0	
After 6-months	8.1 ± 2.2	10.5 ± 3.1	7.8 ± 1.8	
After 1-year	8.3 ± 2.5	10.2 ± 1.8	7.7 ± 2.0	
Trunk (Kg)				
Pre	13.7 <u>+</u> 4.5	15.6 ± 2.3	12.8 ± 2.9	0.513
Post	14.1 ± 5.8	14.7 ± 1.9	12.2 ± 3.2	
After 6-months	13.9 <u>+</u> 5.0	15.3 ± 3.3	12.5 ± 3.1	
After 1-year	14.0 ± 5.5	15.0 ± 2.6	12.3 ± 3.1	
Total fat mass (Kg)				
Pre	24.8 <u>+</u> 7.6	30.1 ± 5.1	24.0 ± 4.8	0.603
Post	25.2 <u>+</u> 8.9	28.8 ± 4.5	23.3 ± 5.6	
After 6-months	24.9 <u>+</u> 7.9	29.4 ± 6.7	23.4 ± 5.2	
After 1-y	25.1 ± 8.7	28.8 ± 4.8	22.9 ± 5.5	
Percentage of fat (S	%)			
Pre	40.4 ± 6.7		39.4 ± 4.1	0.164 ^a
Post	40.5 ± 7.4		37.9 ± 4.8	
After 6-months			38.5 ± 4.2	
After 1-y	40.5 ± 7.1	43.7 ± 3.8	37.6 ± 5.1	
Weight (Kg)				
Pre	60.5 ± 10.1	66.4 ± 7.6	61.9 ± 8.7	0.087
Post	60.9 ± 11.7	63.0 ± 8.0	60.9 ± 8.9	
After 6 months	60.0 ± 10.7	66.0 ± 8.2	60.3 ± 8.7	
After 1 year	60.7 ± 11.3	65.5 ± 6.6	60.5 ± 8.3	

 Table 2.
 Comparison in total and apendicular fat mass variables and

significant differences between groups or interactions for Chol, HDL-c and LDL-c (P > 0.05).

There were no main effects of time (P=0.118) or group (P=0.603) for insulin. For leptin there were no main effects of time (P=0.896) or differences between groups (P=0.379). For adiponectin there were no main effects for time (P=0.661) or group (P=0.294). For PAI-1 there were no main effects for time (P=0.780) or group (P=0.673). There were no statistical interactions (time x group) for any metabolic variable (Table 4).

The linear regression analysis (after 1 year follow-up value minus post-intervention value) showed that trunk fat influenced the changes observed for insulin only in CT group (r=0.48; P=0.025).

For adiponectin, the linear regression analysis showed that the variation was influenced by changes in total fat mass after 1 year follow-up in CT group only (r=0.50; P=0.025). There were no statistically significant associations between body composition, leptin, PAI-1 and lipid profile.

DISCUSSION

The main findings of this study were that 16 weeks of AT and CT improved body composition and some measures of the metabolic profile; however, after 6 months of detraining, LLM returned to pre-training in values CT. Furthermore, AT and CT decreased

LM				
Arm (Kg)				
Pre	4.0 ± 0.7	4.0 ± 0.5	3.8 ± 0.6	0.014
Post	3.9 ± 0.5	4.0 ± 0.4	4.1 ± 0.7	
After 6 months	3.9 ± 0.6	4.0 ± 0.4	4.0 ± 0.7	
After 1-year	3.9 ± 0.7	4.1 ± 0.4	4.1 ± 0.6 ^{a, c}	
Leg (Kg)				
Pre	10.9 ± 1.4	11.1 ± 1.2	11.2 ± 1.5	0.028
Post	10.6 ± 1.3	11.0 ± 1.0	11.6 ± 1.6	
After 6-months	10.5 ± 2.2	10.9 ± 1.1	11.2 ± 1.6 ^b	
After 1-y	10.6 ± 2.5	11.0 ± 0.9	11.4 ± 1.5	
Trunk (Kg)				
Pre	15.7 ± 1.6	15.7 ± 1.9	16.0 ± 2.0	0.948
Post	16.0 ± 2.0	16.2 ± 2.0	16.6 ± 2.1^{a}	
After 6-months	15.7 ± 2.1	16.1 ± 1.7	16.4 ± 2.3	
After 1-y	15.8 ± 1.7	16.1 ± 1.9	16.5 <u>+</u> 2.0	
Total LM (Kg)				
Pre	33.6 ± 3.6	34.0 ± 3.3	34.4 <u>+</u> 4.1	0.027
Post	33.6 ± 3.8	31.7 ± 7.0	35.4 <u>+</u> 4.3	
After 6-months	33.1 ± 7.9	34.2 ± 3.0	34.6 <u>+</u> 4.4	
After 1-y	33.5 ± 3.3	34.4 ± 3.1	35.2 ± 4.0	
Bone mass				
Total BMC (Kg)				
Pre	2.0 ± 0.54	2.4 ± 0.13	2.3 ± 0.34	0.875
Post	2.0 + 0.54	2.3 ± 0.15	2.2 + 0.34	
After 6-months	2.0 ± 0.56	2.4 ± 0.18	2.2 ± 0.36	
After 1-year	2.0 ± 0.52	2.3 ± 0.15	2.2 ± 0.35	
$BMD(g/cm^2)$				
Pre	1.042 ± 0.18	1.140 ± 0.06	1.093 ± 0.10	0.115
Post	1.035 ± 0.17	1.137 ± 0.06	1.102 ± 0.01	
After 6-months	1.035 ± 0.17	1.138 ± 0.07	1.104 ± 0.10	
After 1-year	1.033 ± 0.16	1.146 ± 0.07	1.100 ± 0.10	
Abbreviations: AT, aerobic training; BMC, bone mass content (Kg); BMD, bone mineral density (g/cm ²); CG, control group; CT, concurrent training; LM, lean mass. ^a Tukey's <i>post hoc</i> test with <i>P</i> -value < 0.05 compared with Pre. ^b Tukey's <i>post hoc</i> test with <i>P</i> -value < 0.05 compared with Post. ^c Tukey's <i>post hoc</i> test with <i>P</i> -value < 0.05 compared with that after 6 months.				

Table 3. Comparison in total and apendicular LM and BMD variables

AT (n = 8)

CT (n = 15)

Time x group

CG(n = 8)

glucose, and TAG was decreased in the AT group below baseline after 1 year of cessation of exercise training.

Several studies have investigated the effects of aerobic and CT with a short-term detraining (4–8 weeks)^{26,27} or moderate-term detraining (3–6 months)²⁸ in women, however, little is known about the effects of long-term detraining (≥ 1 year) after in postmenopausal women. Contrary to our results, previous studies have reported a maintenance of fat mass and weight after detraining periods;^{26,29} however, the detraining period in the aforementioned studies was of a shorter duration. Exercises that are able to prevent fat mass regain during detraining periods are important for elderly populations because the elderly are most likely to experience interrupts in exercise programs due to hospitalizations, sickness, disabilities, periods of vacations and travel.²⁶

We found that AT and CT improved total and appendicular LM; however, LLM decreased following 6 months of detraining. A decrease in LM due to the lower number and size of muscle fibers and a decrease in innervated muscle fibers leads to decrease in strength and functional capacity, and increases the risk of falls and resultant fractures, difficulties during activities of daily living, and can result in diseases such as sarcopenia and osteoporosis.³⁰ As lean body mass is an important indicator of

6

mortality,³¹ treatments that attenuate or prevent the loss of LM and bone mass are important during the postmenopausal period.³²

VariablesCG (n=8)AT (n=8)CT (n=15)Time x GroGlucose (mg/dL)Pre97.8 \pm 32.894.5 \pm 26.089.1 \pm 13.40.879 ^{a, b} Post96.6 \pm 20.390.5 \pm 17.388.7 \pm 11.4After93.0 \pm 11.985.8 \pm 11.789.6 \pm 15.56 months6 monthsAfter 1 year97.9 \pm 16.681.9 \pm 5.386.0 \pm 13.1TAG (mg/dL)Pre145.2 \pm 62.998.6 \pm 33.5125.3 \pm 57.60.765 ^b Post129.7 \pm 72.5121.6 \pm 63.5118.5 \pm 72.8After112.6 \pm 47.987.3 \pm 30.4119.8 \pm 55.76 monthsAfter112.6 \pm 47.987.3 \pm 30.4119.8 \pm 55.70.765 ^b Post120.7 \pm 77.283.0 \pm 26.4106.8 \pm 67.10.912Post202.4 \pm 40.4196.2 \pm 38.9200.3 \pm 35.00.912Post202.4 \pm 40.4196.2 \pm 38.9200.3 \pm 35.00.912Post202.4 \pm 40.4196.2 \pm 38.9200.3 \pm 35.00.912Post202.4 \pm 40.4196.2 \pm 38.9200.3 \pm 35.00.912Post10.6 \pm 14.158.1 \pm 12.953.3 \pm 16.00.900Post50.6 \pm 14.158.1 \pm 12.953.3 \pm 16.00.900Post50.4 \pm 16.261.2 \pm 12.759.2 \pm 17.8After49.9 \pm 16.460.1 \pm 6.153.9 \pm 16.16 monthsAfter 1 year54.9 \pm 25.161.4 \pm 12.855.6 \pm 15.9120.2 \pm 25.0 \pm 27.90.594Post <th colspan="6">Table 4. Comparison on the metabolic profile after 6 months and 1-year follow-up</th>	Table 4. Comparison on the metabolic profile after 6 months and 1-year follow-up					
Pre97.8 \pm 32.894.5 \pm 26.089.1 \pm 13.40.879 ^{a, b} Post96.6 \pm 20.390.5 \pm 17.388.7 \pm 11.4After93.0 \pm 11.985.8 \pm 11.789.6 \pm 15.56 monthsAfter 1 year97.9 \pm 16.681.9 \pm 5.386.0 \pm 13.1TAG (mg/dL)Pre145.2 \pm 62.998.6 \pm 33.5125.3 \pm 57.60.765 ^b Post129.7 \pm 72.5121.6 \pm 63.5118.5 \pm 72.8After112.6 \pm 47.987.3 \pm 30.4119.8 \pm 55.76 monthsAfter112.6 \pm 47.987.3 \pm 30.4119.8 \pm 55.76 monthsAfter 1 year144.7 \pm 77.283.0 \pm 26.4106.8 \pm 67.10.912Pre205.5 \pm 32.0198.9 \pm 38.3203.3 \pm 32.00.912Post202.4 \pm 40.4196.2 \pm 38.9200.3 \pm 35.0After188.1 \pm 27.5176.8 \pm 24.6194.2 \pm 31.96 monthsAfter188.1 \pm 27.5176.8 \pm 24.6194.2 \pm 31.50.912Post50.4 \pm 16.261.2 \pm 12.759.2 \pm 17.8AfterAfter 1 year190.1 \pm 37.1189.3 \pm 28.4201.8 \pm 31.50.900Post51.6 \pm 14.158.1 \pm 12.953.3 \pm 16.00.900Post50.4 \pm 16.261.2 \pm 12.759.2 \pm 17.8After49.9 \pm 16.460.1 \pm 6.153.9 \pm 16.166 monthsAfter 1 year54.9 \pm 25.161.4 \pm 12.855.6 \pm 15.915.915.6 \pm 29.099.1 \pm 29.0	oup					
Post 96.6 \pm 20.3 90.5 \pm 17.3 88.7 \pm 11.4 After 93.0 \pm 11.9 85.8 \pm 11.7 89.6 \pm 15.5 6 months After 1 year 97.9 \pm 16.6 81.9 \pm 5.3 86.0 \pm 13.1 TAG (mg/dL) Pre 145.2 \pm 62.9 98.6 \pm 33.5 125.3 \pm 57.6 Post 129.7 \pm 72.5 121.6 \pm 63.5 118.5 \pm 72.8 After 112.6 \pm 47.9 87.3 \pm 30.4 119.8 \pm 55.7 6 months After 1 year 144.7 \pm 77.2 83.0 \pm 26.4 106.8 \pm 67.1 Chol (mg/dL) Pre 205.5 \pm 32.0 198.9 \pm 38.3 203.3 \pm 32.0 Post 202.4 \pm 40.4 196.2 \pm 38.9 200.3 \pm 35.0 After 188.1 \pm 27.5 176.8 \pm 24.6 194.2 \pm 31.9 6 months After 1 year 190.1 \pm 37.1 189.3 \pm 28.4 201.8 \pm 31.5 HDL-c (mg/dL) Pre 51.6 \pm 14.1 58.1 \pm 12.9 53.3 \pm 16.0 Post 50.4 \pm 16.2 61.2 \pm 12.7 59.2 \pm 17.8 After 49.9 \pm 16.4 60.1 \pm 6.1 \pm 53.9 \pm 16.1 6 months After 1 year 54.9 \pm 25.1 61.4 \pm 12.8 55.6 \pm 15.9 LDL-c (mg/dL) Pre 125.0 \pm 34.0 121.2 \pm 35.2 125.0 \pm 27.9 Post 126.0 \pm 27.9 111.2 \pm 30.7 116.1 \pm 31.7 After 115.6 \pm 29.0 99.1 \pm 29.0 116.4 \pm 27.2 6 months After 1 year 106.3 \pm 30.8 111.4 \pm 31.2 124.8 \pm 26.1						
After 93.0 ± 11.9 85.8 ± 11.7 89.6 ± 15.5 6 months After 1 year 97.9 ± 16.6 81.9 ± 5.3 86.0 ± 13.1 TAG (mg/dL) Pre 145.2 ± 62.9 98.6 ± 33.5 125.3 ± 57.6 Post 129.7 ± 72.5 121.6 ± 63.5 118.5 ± 72.8 After 112.6 ± 47.9 87.3 ± 30.4 119.8 ± 55.7 6 months After 1 year 144.7 ± 77.2 83.0 ± 26.4 106.8 ± 67.1 Chol (mg/dL) Pre 205.5 ± 32.0 198.9 ± 38.3 203.3 ± 32.0 Post 202.4 ± 40.4 196.2 ± 38.9 200.3 ± 35.0 After 188.1 ± 27.5 176.8 ± 24.6 194.2 ± 31.9 6 months After 1 year 190.1 ± 37.1 189.3 ± 28.4 201.8 ± 31.5 HDL-c (mg/dL) Pre 51.6 ± 14.1 58.1 ± 12.9 53.3 ± 16.0 Post 50.4 ± 16.2 61.2 ± 12.7 59.2 ± 17.8 After 49.9 ± 16.4 60.1 ± 6.1 53.9 ± 16.1 6 months After 1 year 54.9 ± 25.1 61.4 ± 12.8 55.6 ± 15.9 LDL-c (mg/dL) Pre 125.0 ± 34.0 121.2 ± 35.2 125.0 ± 27.9 Post 126.0 ± 27.9 111.2 ± 30.7 116.1 ± 31.7 After 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 months After 1 year 106.3 ± 30.8 111.4 ± 31.2 124.8 ± 26.1	,					
$\begin{array}{c} 6 \text{ months} \\ \text{After 1 year} \\ 97.9 \pm 16.6 \\ 81.9 \pm 5.3 \\ 86.0 \pm 13.1 \\ \hline \\ \textbf{TAG } (mg/dL) \\ \text{Pre} \\ 145.2 \pm 62.9 \\ \text{Post} \\ 129.7 \pm 72.5 \\ 121.6 \pm 63.5 \\ 118.5 \pm 72.8 \\ \text{After} \\ 112.6 \pm 47.9 \\ 87.3 \pm 30.4 \\ 119.8 \pm 55.7 \\ 6 \text{ months} \\ \text{After 1 year} \\ 144.7 \pm 77.2 \\ 83.0 \pm 26.4 \\ 106.8 \pm 67.1 \\ \hline \\ \textbf{Chol } (mg/dL) \\ \text{Pre} \\ 205.5 \pm 32.0 \\ 198.9 \pm 38.3 \\ 203.3 \pm 32.0 \\ 202.4 \pm 40.4 \\ 196.2 \pm 38.9 \\ 200.3 \pm 35.0 \\ \text{After} \\ 188.1 \pm 27.5 \\ 176.8 \pm 24.6 \\ 194.2 \pm 31.9 \\ 6 \text{ months} \\ \text{After 1 year} \\ 190.1 \pm 37.1 \\ 189.3 \pm 28.4 \\ 201.8 \pm 31.5 \\ \hline \\ \textbf{HDL-c } (mg/dL) \\ \text{Pre} \\ 51.6 \pm 14.1 \\ 58.1 \pm 12.9 \\ 53.3 \pm 16.0 \\ 60.1 \pm 6.1 \\ 53.9 \pm 16.1 \\ 6 \text{ months} \\ \text{After 1 year} \\ 50.4 \pm 16.2 \\ 61.2 \pm 12.7 \\ 59.2 \pm 17.8 \\ \text{After} \\ 49.9 \pm 16.4 \\ 60.1 \pm 6.1 \\ 53.9 \pm 16.1 \\ 6 \text{ months} \\ \text{After 1 year} \\ 54.9 \pm 25.1 \\ 61.4 \pm 12.8 \\ 55.6 \pm 15.9 \\ \hline \\ \textbf{LDL-c } (mg/dL) \\ \text{Pre} \\ 125.0 \pm 34.0 \\ 121.2 \pm 35.2 \\ 125.0 \pm 27.9 \\ 111.2 \pm 30.7 \\ 116.1 \pm 31.7 \\ \text{After} \\ 115.6 \pm 29.0 \\ 99.1 \pm 29.0 \\ 116.4 \pm 27.2 \\ 6 \text{ months} \\ \text{After 1 year} \\ 106.3 \pm 30.8 \\ 111.4 \pm 31.2 \\ 124.8 \pm 26.1 \\ \hline \end{array}$						
After 1 year 97.9 ± 16.6 81.9 ± 5.3 86.0 ± 13.1 TAG (mg/dL) Pre 145.2 ± 62.9 98.6 ± 33.5 125.3 ± 57.6 0.765 ^b Post 129.7 ± 72.5 121.6 ± 63.5 118.5 ± 72.8 After 112.6 ± 47.9 87.3 ± 30.4 119.8 ± 55.7 6 months After 1 year 144.7 ± 77.2 83.0 ± 26.4 106.8 ± 67.1 Chol (mg/dL) Pre 205.5 ± 32.0 198.9 ± 38.3 203.3 ± 32.0 0.912 Post 202.4 ± 40.4 196.2 ± 38.9 200.3 ± 35.0 After 188.1 ± 27.5 176.8 ± 24.6 194.2 ± 31.9 6 months After 1 year 190.1 ± 37.1 189.3 ± 28.4 201.8 ± 31.5 HDL-c (mg/dL) Pre 51.6 ± 14.1 58.1 ± 12.9 53.3 ± 16.0 0.900 Post 50.4 ± 16.2 61.2 ± 12.7 59.2 ± 17.8 After 49.9 ± 16.4 60.1 ± 6.1 53.9 ± 16.1 6 months After 1 year 54.9 ± 25.1 61.4 ± 12.8 55.6 ± 15.9 LDL-c (mg/dL) Pre 125.0 ± 34.0 121.2 ± 35.2 125.0 ± 27.9 0.594 Post 126.0 ± 27.9 111.2 ± 30.7 116.1 ± 31.7 After 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 months After 1 year 106.3 ± 30.8 111.4 ± 31.2 124.8 ± 26.1						
Pre 145.2 ± 62.9 98.6 ± 33.5 125.3 ± 57.6 0.765^b Post 129.7 ± 72.5 121.6 ± 63.5 118.5 ± 72.8 After 112.6 ± 47.9 87.3 ± 30.4 119.8 ± 55.7 6 monthsAfter 1 year 144.7 ± 77.2 83.0 ± 26.4 106.8 ± 67.1 Chol (mg/dL)Pre 205.5 ± 32.0 198.9 ± 38.3 203.3 ± 32.0 0.912 Post 202.4 ± 40.4 196.2 ± 38.9 200.3 ± 35.0 $After$ 188.1 ± 27.5 176.8 ± 24.6 194.2 ± 31.9 6 monthsAfter 188.1 ± 27.5 176.8 ± 24.6 194.2 ± 31.5 0.900 Post 51.6 ± 14.1 58.1 ± 12.9 53.3 ± 16.0 0.900 Post 50.4 ± 16.2 61.2 ± 12.7 59.2 ± 17.8 0.900 Post 50.4 ± 16.2 61.2 ± 12.7 59.2 ± 17.8 $4fter$ 49.9 ± 16.4 60.1 ± 6.1 53.9 ± 16.1 6 monthsAfter 49.9 ± 16.4 60.1 ± 6.1 53.9 ± 16.1 6 0.594 Post 54.9 ± 25.1 61.4 ± 12.8 55.6 ± 15.9 126.0 ± 27.9 111.2 ± 30.7 116.1 ± 31.7 After 112.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 6 6 After 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 6 6 monthsAfter 196.3 ± 30.8 111.4 ± 31.2 124.8 ± 26.1						
Post 129.7 ± 72.5 121.6 ± 63.5 118.5 ± 72.8 After 112.6 ± 47.9 87.3 ± 30.4 119.8 ± 55.7 6 months $After 1$ year 144.7 ± 77.2 83.0 ± 26.4 106.8 ± 67.1 Chol (mg/dL)Pre 205.5 ± 32.0 198.9 ± 38.3 203.3 ± 32.0 0.912 Post 202.4 ± 40.4 196.2 ± 38.9 200.3 ± 35.0 $After$ 188.1 ± 27.5 176.8 ± 24.6 194.2 ± 31.9 6 months $After$ 188.1 ± 27.5 176.8 ± 24.6 194.2 ± 31.5 0.900 Post 202.4 ± 16.2 61.2 ± 12.7 59.2 ± 17.8 $After$ After 1 year 190.1 ± 37.1 189.3 ± 28.4 201.8 ± 31.5 0.900 Post 50.4 ± 16.2 61.2 ± 12.7 59.2 ± 17.8 $After$ After 49.9 ± 16.4 60.1 ± 6.1 53.9 ± 16.1 6 6 months $After$ 49.9 ± 25.1 61.4 ± 12.8 55.6 ± 15.9 LDL-c (mg/dL)Pre 125.0 ± 34.0 121.2 ± 35.2 125.0 ± 27.9 0.594 Post 126.0 ± 27.9 111.2 ± 30.7 116.1 ± 31.7 $After$ 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 months $After$ 198.3 ± 30.8 111.4 ± 31.2 124.8 ± 26.1 24.8 ± 26.1						
After 112.6 ± 47.9 87.3 ± 30.4 119.8 ± 55.7 6monthsAfter 1 year 144.7 ± 77.2 83.0 ± 26.4 106.8 ± 67.1 0.912Pre 205.5 ± 32.0 198.9 ± 38.3 203.3 ± 32.0 0.912Post 202.4 ± 40.4 196.2 ± 38.9 200.3 ± 35.0 0.912After 188.1 ± 27.5 176.8 ± 24.6 194.2 ± 31.9 0.9126 months $After$ 190.1 ± 37.1 189.3 ± 28.4 201.8 ± 31.5 HDL-c (mg/dL)Pre 51.6 ± 14.1 58.1 ± 12.9 53.3 ± 16.0 0.900Post 50.4 ± 16.2 61.2 ± 12.7 59.2 ± 17.8 0.900Post 50.4 ± 16.2 61.2 ± 12.7 59.2 ± 17.8 0.900Post 50.4 ± 16.2 $61.1 \pm 53.9 \pm 16.1$ 0.900Fre 125.0 ± 34.0 121.2 ± 35.2 125.0 ± 27.9 0.594Post 126.0 ± 27.9 111.2 ± 30.7 116.1 ± 31.7 AfterAfter 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 66monthsAfter 1 year 106.3 ± 30.8 111.4 ± 31.2 124.8 ± 26.1						
$\begin{array}{l} 6 \text{ months} \\ \text{After 1 year } 144.7 \pm 77.2 \\ 83.0 \pm 26.4 \\ 106.8 \pm 67.1 \\ \hline \\ \begin{array}{l} \text{Chol } (mg/dL) \\ \text{Pre} \\ 205.5 \pm 32.0 \\ 198.9 \pm 38.3 \\ 203.3 \pm 32.0 \\ 202.4 \pm 40.4 \\ 196.2 \pm 38.9 \\ 200.3 \pm 35.0 \\ \text{After} \\ 188.1 \pm 27.5 \\ 176.8 \pm 24.6 \\ 194.2 \pm 31.9 \\ 6 \text{ months} \\ \text{After 1 year } 190.1 \pm 37.1 \\ 189.3 \pm 28.4 \\ 201.8 \pm 31.5 \\ \hline \\ \begin{array}{l} \text{HDL-c } (mg/dL) \\ \text{Pre} \\ 51.6 \pm 14.1 \\ 58.1 \pm 12.9 \\ 53.3 \pm 16.0 \\ 61.2 \pm 12.7 \\ 59.2 \pm 17.8 \\ \text{After } \\ 49.9 \pm 16.4 \\ 60.1 \pm 6.1 \\ 53.9 \pm 16.1 \\ 6 \text{ months} \\ \text{After 1 year } 54.9 \pm 25.1 \\ 61.4 \pm 12.8 \\ 55.6 \pm 15.9 \\ \hline \\ \begin{array}{l} \text{LDL-c } (mg/dL) \\ \text{Pre} \\ 125.0 \pm 34.0 \\ 121.2 \pm 35.2 \\ 125.0 \pm 27.9 \\ 111.2 \pm 30.7 \\ 116.1 \pm 31.7 \\ \text{After } \\ 115.6 \pm 29.0 \\ 99.1 \pm 29.0 \\ 116.4 \pm 27.2 \\ 6 \text{ months} \\ \text{After 1 year } 106.3 \pm 30.8 \\ 111.4 \pm 31.2 \\ 124.8 \pm 26.1 \\ \end{array}$						
After 1 year 144.7 ± 77.2 83.0 ± 26.4 106.8 ± 67.1 <i>Chol (mg/dL)</i> Pre 205.5 ± 32.0 198.9 ± 38.3 203.3 ± 32.0 0.912 Post 202.4 ± 40.4 196.2 ± 38.9 200.3 ± 35.0 After 188.1 ± 27.5 176.8 ± 24.6 194.2 ± 31.9 6 months After 1 year 190.1 ± 37.1 189.3 ± 28.4 201.8 ± 31.5 <i>HDL-c (mg/dL)</i> Pre 51.6 ± 14.1 58.1 ± 12.9 53.3 ± 16.0 0.900 Post 50.4 ± 16.2 61.2 ± 12.7 59.2 ± 17.8 After 49.9 ± 16.4 60.1 ± 6.1 53.9 ± 16.1 6 months After 1 year 54.9 ± 25.1 61.4 ± 12.8 55.6 ± 15.9 <i>LDL-c (mg/dL)</i> Pre 125.0 ± 34.0 121.2 ± 35.2 125.0 ± 27.9 0.594 Post 126.0 ± 27.9 111.2 ± 30.7 116.1 ± 31.7 After 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 months After 1 year 106.3 ± 30.8 111.4 ± 31.2 124.8 ± 26.1						
Pre 205.5 ± 32.0 198.9 ± 38.3 203.3 ± 32.0 0.912 Post 202.4 ± 40.4 196.2 ± 38.9 200.3 ± 35.0 After 188.1 ± 27.5 176.8 ± 24.6 194.2 ± 31.9 6 monthsAfter 1 year 190.1 ± 37.1 189.3 ± 28.4 201.8 ± 31.5 HDL-c (mg/dL)Pre 51.6 ± 14.1 58.1 ± 12.9 53.3 ± 16.0 Post 50.4 ± 16.2 61.2 ± 12.7 59.2 ± 17.8 After 49.9 ± 16.4 60.1 ± 6.1 53.9 ± 16.1 6 months $After 1$ year 54.9 ± 25.1 61.4 ± 12.8 55.6 ± 15.9 LDL-c (mg/dL)Pre 125.0 ± 34.0 121.2 ± 35.2 125.0 ± 27.9 Post 126.0 ± 27.9 111.2 ± 30.7 116.1 ± 31.7 After 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 months $After 1$ year 106.3 ± 30.8 111.4 ± 31.2 124.8 ± 26.1						
Pre 205.5 ± 32.0 198.9 ± 38.3 203.3 ± 32.0 0.912 Post 202.4 ± 40.4 196.2 ± 38.9 200.3 ± 35.0 After 188.1 ± 27.5 176.8 ± 24.6 194.2 ± 31.9 6 monthsAfter 1 year 190.1 ± 37.1 189.3 ± 28.4 201.8 ± 31.5 HDL-c (mg/dL)Pre 51.6 ± 14.1 58.1 ± 12.9 53.3 ± 16.0 Post 50.4 ± 16.2 61.2 ± 12.7 59.2 ± 17.8 After 49.9 ± 16.4 60.1 ± 6.1 53.9 ± 16.1 6 months $After 1$ year 54.9 ± 25.1 61.4 ± 12.8 55.6 ± 15.9 LDL-c (mg/dL)Pre 125.0 ± 34.0 121.2 ± 35.2 125.0 ± 27.9 Post 126.0 ± 27.9 111.2 ± 30.7 116.1 ± 31.7 After 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 months $After 1$ year 106.3 ± 30.8 111.4 ± 31.2 124.8 ± 26.1						
Post After 202.4 ± 40.4 188.1 ± 27.5 196.2 ± 38.9 176.8 ± 24.6 200.3 ± 35.0 194.2 ± 31.9 6 months After 1 year 190.1 ± 37.1 190.1 ± 37.1 189.3 ± 28.4 201.8 ± 31.5 0000 104.2 ± 31.5 HDL-c (mg/dL) Pre0.900 10.4 ± 16.2 0.900 61.2 ± 12.7 0.900 $905 \pm 50.4 \pm 16.2$ 61.2 ± 12.7 0.900 $905 \pm 50.4 \pm 16.2$ 61.2 ± 12.7 0.900Pre51.6 \pm 14.1 58.1 ± 12.9 53.3 \pm 16.0 53.9 ± 16.1 6 months After 1 year0.9900 9.1 ± 25.1 0.900DST0.99 \pm 16.4 60.1 ± 6.1 0.99 \pm 16.1 53.9 ± 16.1 6 months After 1 year0.594DL-c (mg/dL) Pre125.0 \pm 34.0 121.2 ± 35.2 125.0 \pm 27.9 111.2 ± 30.7 116.1 ± 31.7 After After After 1 15.6 \pm 29.0 99.1 ± 29.0 0.594After 1 year106.3 \pm 30.8111.4 \pm 31.2 124.8 ± 26.1						
$\begin{array}{l} 6 \text{ months} \\ \text{After 1 year } 190.1 \pm 37.1 \\ 189.3 \pm 28.4 \\ 201.8 \pm 31.5 \\ \hline \\ \textbf{HDL-c (mg/dL)} \\ \text{Pre} \\ 51.6 \pm 14.1 \\ 58.1 \pm 12.9 \\ 53.3 \pm 16.0 \\ \text{Post} \\ 50.4 \pm 16.2 \\ 61.2 \pm 12.7 \\ 59.2 \pm 17.8 \\ \text{After} \\ 49.9 \pm 16.4 \\ 60.1 \pm 6.1 \\ 53.9 \pm 16.1 \\ 6 \text{ months} \\ \text{After 1 year } 54.9 \pm 25.1 \\ 61.4 \pm 12.8 \\ 55.6 \pm 15.9 \\ \hline \\ \textbf{LDL-c (mg/dL)} \\ \text{Pre} \\ 125.0 \pm 34.0 \\ 121.2 \pm 35.2 \\ 125.0 \pm 27.9 \\ \text{Post} \\ 126.0 \pm 27.9 \\ 111.2 \pm 30.7 \\ 116.1 \pm 31.7 \\ \text{After 1 15.6 \pm 29.0 } 99.1 \pm 29.0 \\ 116.4 \pm 27.2 \\ 6 \text{ months} \\ \text{After 1 year 106.3 \pm 30.8 } \\ 111.4 \pm 31.2 \\ 124.8 \pm 26.1 \\ \hline \end{array}$						
After 1 year 190.1 ± 37.1 189.3 ± 28.4 201.8 ± 31.5 <i>HDL-c (mg/dL)</i> Pre 51.6 ± 14.1 58.1 ± 12.9 53.3 ± 16.0 0.900 Post 50.4 ± 16.2 61.2 ± 12.7 59.2 ± 17.8 After 49.9 ± 16.4 60.1 ± 6.1 53.9 ± 16.1 6 months After 1 year 54.9 ± 25.1 61.4 ± 12.8 55.6 ± 15.9 <i>LDL-c (mg/dL)</i> Pre 125.0 ± 34.0 121.2 ± 35.2 125.0 ± 27.9 0.594 Post 126.0 ± 27.9 111.2 ± 30.7 116.1 ± 31.7 After 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 months After 1 year 106.3 ± 30.8 111.4 ± 31.2 124.8 ± 26.1						
$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$						
Pre 51.6 ± 14.1 58.1 ± 12.9 53.3 ± 16.0 0.900 Post 50.4 ± 16.2 61.2 ± 12.7 59.2 ± 17.8 After 49.9 ± 16.4 60.1 ± 6.1 53.9 ± 16.1 6 monthsAfter 1 year 54.9 ± 25.1 61.4 ± 12.8 55.6 ± 15.9 LDL-c (mg/dL)Pre 125.0 ± 34.0 121.2 ± 35.2 125.0 ± 27.9 0.594 Post 126.0 ± 27.9 111.2 ± 30.7 116.1 ± 31.7 $After$ 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 months $After$ 1 year 106.3 ± 30.8 111.4 ± 31.2 124.8 ± 26.1						
Post 50.4 ± 16.2 61.2 ± 12.7 59.2 ± 17.8 After 49.9 ± 16.4 60.1 ± 6.1 53.9 ± 16.1 6 monthsAfter 1 year 54.9 ± 25.1 61.4 ± 12.8 55.6 ± 15.9 LDL-c (mg/dL)Pre 125.0 ± 34.0 121.2 ± 35.2 125.0 ± 27.9 0.594 Post 126.0 ± 27.9 111.2 ± 30.7 116.1 ± 31.7 AfterAfter 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 6 months $After 1$ year 106.3 ± 30.8 111.4 ± 31.2 124.8 ± 26.1						
After 49.9 ± 16.4 60.1 ± 6.1 53.9 ± 16.1 6 monthsAfter 1 year 54.9 ± 25.1 61.4 ± 12.8 55.6 ± 15.9 LDL-c (mg/dL)Pre 125.0 ± 34.0 121.2 ± 35.2 125.0 ± 27.9 0.594 Post 126.0 ± 27.9 111.2 ± 30.7 116.1 ± 31.7 $After$ 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 monthsAfter 1 year 106.3 ± 30.8 111.4 ± 31.2 124.8 ± 26.1						
6 months After 1 year 54.9 ± 25.1 61.4 ± 12.8 55.6 ± 15.9 <i>LDL-c (mg/dL)</i> Pre 125.0 ± 34.0 121.2 ± 35.2 125.0 ± 27.9 Post 126.0 ± 27.9 111.2 ± 30.7 116.1 ± 31.7 After 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 months After 1 year 106.3 ± 30.8 111.4 ± 31.2 124.8 ± 26.1						
After 1 year 54.9 ± 25.1 61.4 ± 12.8 55.6 ± 15.9 LDL-c (mg/dL)Pre 125.0 ± 34.0 121.2 ± 35.2 125.0 ± 27.9 0.594 Post 126.0 ± 27.9 111.2 ± 30.7 116.1 ± 31.7 After 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 months 6 106.3 ± 30.8 111.4 ± 31.2 124.8 \pm 26.1						
Pre 125.0 ± 34.0 121.2 ± 35.2 125.0 ± 27.9 0.594 Post 126.0 ± 27.9 111.2 ± 30.7 116.1 ± 31.7 After 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 monthsAfter 1 year 106.3 ± 30.8 111.4 ± 31.2 124.8 \pm 26.1						
Pre 125.0 ± 34.0 121.2 ± 35.2 125.0 ± 27.9 0.594 Post 126.0 ± 27.9 111.2 ± 30.7 116.1 ± 31.7 After 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 monthsAfter 1 year 106.3 ± 30.8 111.4 ± 31.2 124.8 \pm 26.1						
Post 126.0 ± 27.9 111.2 ± 30.7 116.1 ± 31.7 After 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 monthsAfter 1 year 106.3 ± 30.8 111.4 ± 31.2 124.8 ± 26.1						
After 115.6 ± 29.0 99.1 ± 29.0 116.4 ± 27.2 6 monthsAfter 1 year 106.3 ± 30.8 111.4 ± 31.2 124.8 ± 26.1						
6 months After 1 year 106.3 \pm 30.8 111.4 \pm 31.2 124.8 \pm 26.1						
After 1 year 106.3 ± 30.8 111.4 ± 31.2 124.8 ± 26.1						
Insulin (μIU/ml)						
Pre – 5.84 ± 2.7 5.25 ± 1.7						
Post $-$ 5.00 \pm 3.6 5.40 \pm 5.6 0.472						
After – – –						
6 months						
After 1 year – 7.00 ± 2.3 7.03 ± 3.6						
HOMA-IR						
Pre - 1.47 ± 1.1 1.15 ± 0.5						
Post – 1.16 ± 0.9 1.23 ± 1.3 0.714 After – – – –						
6 months						
After 1 year $-$ 1.42 ± 0.5 1.41 ± 0.9						
Leptin (ng/mL)						
Pre 94.2 \pm 59.8 100.6 \pm 48.0 74.7 \pm 36.4						
Post $ 83.9 \pm 23.3$ 81.1 ± 36.2 0.587						
After – – –						
6 months						
After 1 year – 101.5 ± 43.0 78.5 ± 34.7						
Adiponectin (ug/mL)						
Pre 8.4 ± 4.7 11.6 ± 1.8 10.9 ± 3.5						
Post – 11.8±0.9 11.0±2.5 0.984						
After – – –						
6 months						
After - 12.3 ± 0.4 11.2 ± 2.3						
1 year						

Our findings are consistent with the results of the Delshad et al.²⁶ that examined the effect of 12 weeks of resistance exercise training (three sets of 10 repetitions and 80-100% 10-RM), three times a week followed by 4 weeks of detraining, on muscle mass in postmenopausal women and reported that these values were maintained after the detraining period. Melnyk et al.33 investigated the effects of 9 weeks of strength training on regional muscle area in young and older men and women (20-30 years old and 65-75 years old) following 31 weeks of detraining and found that strength training induced increases in cross-sectional area of the quadriceps, but after the detraining period these values returned to baseline. In agreement, Correa et al.³⁴ analyzed knee extensors, elbow flexor muscle strength, rectus femoris muscle volume and functional performance in older female adults after 12 weeks of strength training followed by 1 year of detraining and then 12 weeks of retraining. Detraining resulted in a decrease in strength and muscle volume and these parameters were increased after retraining, reiterating that it is important not only to encourage people to start a training program but also to encourage these participants to maintain the exercise program.

In regard to the metabolic profile, plasma glucose was decreased in CT and AT when compared with CG, and TAG was reduced in the AT group in comparison with CG. The hyperglycemic state is a strong indicator of lower insulin sensitivity, and it has been reported that 40% of the population with diminished glucose tolerance develops type 2 diabetes mellitus in 5-10 years.³⁵ After 1 year follow-up, glucose was reduced by 3% in CT and by 9.5% in AT group when compared with post-intervention period. Insulin-mediated glucose uptake by skeletal muscle is directly related to total muscle mass and inversely associated with fat mass,³⁶ which is in accordance with our results as we found a strong negative relationship between LM and plasma glucose. The AT and CT groups likely increased glucose uptake via enhanced insulin receptor signaling, messenger RNA expression of the glucose transporter (GLUT-4) and the enzymatic activity of alvcogen synthase.³

Regular and acute physical exercise promotes a decrease in TAG concentrations.³⁸ This outcome occurs because physical training promotes a decrease in adipose tissue, especially central adiposity, which is an important source of fatty-free acids to TAG secretion in overweight/obese people.³⁹ The results of a recent study suggest that exercise can augment VLDL-TAG affinity for LPL, thereby, delivering more TAG toward peripheral tissues for metabolism, which decreases its concentration in plasma.⁴⁰

HDL-c was increased and LDL-c was decreased following 16weeks of training for CT and AT groups; however, there were no significant differences between groups and after 6 months of detraining HDL-c returned to baseline values. A reduction in HDL-c

Table 4. (Continu	ued)					
Variables	CG (n = 8)	AT (n = 8)	CT (n = 15)	Time x Group		
PAI-1 (ng/ml)						
Pre	26.6 ± 22.7	12.7 ± 4.8	17.7 <u>+</u> 19.6			
Post	-	15.5 ± 5.2	15.9 <u>+</u> 6.4	0.917		
After	-	_	-			
6 months						
After 1 year	-	18.0 ± 15.6	20.3 ± 20.5			
Abbreviations: AT, aerobic training; chol, total cholesterol; CG, control group; CT, concurrent training; HDL-c, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment-insulin resistance; LDL-c, low-density lipoprotein cholesterol concentration; PAI-1, plasminogen activator inhibitor-1; TAG, triacylglycerol. ^a Statistically significant differences between CT and CG groups. ^b Statistically significant differences between						

AT and CG groups.

and increase in LDL-c increases the risk of developing cardiovascular diseases as the fractions of LDL cholesterol are more susceptible to oxidation and cause greater accumulation in the arterial wall,⁴¹ and the HDL-c fractions perform reverse cholesterol transport.⁴² Studies have demonstrated that systematic exercise could increase levels of apo-A1 that protects the arterial walls, and could decrease levels of apo-B that promotes atherosclerosis.⁴³ Among the inhibitory factors, the rapid acting PAI-1 is one of the most important inhibitors of the plasma fibrinolytic activity,⁴⁴ and its expression is significantly enhanced in a variety of clinical conditions such as old age, obesity, insulin resistance and increased inflammation.⁴⁵ Despite training, we did not find a significant difference in PAI-1 between pre-training or posttraining.

The limitations of this study need to be considered when interpreting the findings. The follow-up time may have been insufficient to verify differences between groups and 16 wks of training may have been insufficient to improve BMD, as one study demonstrated positive effects in this variable only after 12 months of training;⁴⁶ thus, we recommend future studies analyze the time-course of CT detraining at more frequent intervals. In addition, the few number of participants in each group after detraining and the differences in body composition results are expected with different energy expenditures, which may be related not only to the type of exercise but also with the energy expenditure associated. In addition, future studies should investigate functional capacity, hemodynamics and performance following detraining.

Despite these limitations, it should be highlighted that this study controlled for dietary intake and free-living PA during the 1 year follow-up to minimize the influence of these variables on the outcomes. Although the tri-axial accelerometer was used to provide a measurement of free-living PA of the participants, the accelerometer is known not to measure all PA, as it underestimates activity conducted primarily above the waist, such as sweeping or carrying a load, and it is possible that these activities could have been used frequently by the participants, especially as 62.5% were retired. Anjos et al.47 investigated the PA level in 1689 men and women of different ages, through 24-h recall, and observed that most of the participants met the 30 min of PA recommended by the ACSM;⁴⁸ however, the men accumulated greater moderate to vigorous activity during leisure activities and the women during domestic activities, suggesting that, these patterns could have influenced our results in relation to the gain in arm LM after 1-year follow-up.

In conclusion, both aerobic and CT similarly improved total and appendicular body composition and metabolic profile after 16 weeks of training and some of these values were maintained through the follow-up period; however, after 6 months of detraining there was reduction in LLM. Metabolic profile was influenced by body composition changes after 1 year follow-up and this may have been the result of differences in energy intake. Our results highlight the benefits of regular exercise and emphasize the importance of maintaining an exercise training program over a prolonged period in postmenopausal women.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- Toth MJ, Tchernof A, Sites CK, Poehlman ET. Effect of menopausal status on body composition and abdominal fat distribution. *Int J Obes Relat Metab Disord* 2000; 24: 226–231.
- 2 Polotsky HN, Polotsky AJ. Metabolic implications of menopause. *Semin Reprod Med* 2010; **28**: 426–434.

- 3 Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N *et al.* Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 2008; **117**: e25–146.
- 4 Chodzko-Zajko WJ, Proctor DN, Fiatarone Singh MA, Minson CT, Nigg CR, Salem GJ et al. American College of Sports Medicine position stand. Exercise and physical activity for older adults. *Med Sci Sports Exerc* 2009; **41**: 1510–1530.
- 5 Ruffino JS, Davies NA, Morris K, Ludgate M, Zhang L, Webb R *et al.* Moderateintensity exercise alters markers of alternative activation in circulating monocytes in females: a putative role for PPARgamma. *Eur J Appl Physiol* 2016; **116**: 1671–1682.
- 6 Jeukendrup AE, Saris WH, Wagenmakers AJ. Fat metabolism during exercise: a review. Part I: fatty acid mobilization and muscle metabolism. *Int J Sports Med* 1998; **19**: 231–244.
- 7 Friedenreich C, Woolcott C, McTiernan A, Terry T, Brant R, Ballard-Barbash R et al. Adiposity changes after a 1-year aerobic exercise intervention among postmenopausal women: a randomized controlled trial. Int J Obes 2011; 35: 427–435.
- 8 Kelley GA, Kelley KS, Tran ZV. Aerobic exercise and lipids and lipoproteins in women: a meta-analysis of randomized controlled trials. J Womens Health 2004; 13: 1148–1164.
- 9 Silva NL, Oliveira RB, Fleck SJ, Leon AC, Farinatti P. Influence of strength training variables on strength gains in adults over 55 years-old: a meta-analysis of dose-response relationships. *J Sci Med Sport* 2014; **17**: 337–344.
- 10 Rossi FE, Buonani C, Viezel J, Gerosa-Neto J, Mota J, Fernandes R *et al.* [Effects of concurrent training on body composition and resting metabolic rate in postmenopausal women]. *RPCD* 2013; **13**: 12–22.
- 11 Rossi FE, Buonani C, Viezel J, EP da Silva, Diniz TA, VR dos Santos et al. Effect of combined aerobic and resistance training in body composition of obese postmenopausal women. *Motriz Revista de Educação Física* 2015; 21: 61–67.
- 12 Rossi FE, Fortaleza AC, Neves LM, Buonani C, Picolo MR, Diniz TA *et al.* Combined training (aerobic plus strength) potentiates a reduction in body fat but demonstrates no difference on the lipid profile in postmenopausal women when compared to aerobic training with a similar training load. *J Strength Cond Res* 2015; **30**: 226–234.
- 13 Mitsuhashi T, Yamada C, Iida A, Hiratsuka N, Inabe F, Araida N et al. Long-term detraining increases the risk of metabolic syndrome in Japanese men. Tokai J Exp Clin Med 2011; 4: 95–99.
- 14 Hauer K, Pfisterer M, Schuler M, Bärtsch P, Oster P. Two years later: a prospective long-term follow-up of a training intervention in geriatric patients with a history of severe falls. Arch Phys Med Rehabil 2003; 84: 1426–1432.
- 15 Mora-Rodriguez R, Ortega JF, Hamouti N, Fernandez-Elias VE, Canete Garcia-Prieto J, Guadalupe-Grau A *et al.* Time-course effects of aerobic interval training and detraining in patients with metabolic syndrome. *Nutr Metab Cardiovasc Dis* 2014; 24: 792–798.
- 16 Lo MS, Lin LL, Yao WJ, Ma MC. Training and detraining effects of the resistance vs. endurance program on body composition, body size, and physical performance in young men. J Strength Cond Res 2011; 25: 2246–2254.
- 17 Egbewale BE. Random allocation in controlled clinical trials: a review. J Pharm Pharm Sci 2014; **17**: 248–253.
- 18 Bhupathiraju SN, Dawson-Hughes B, Hannan MT, Lichtenstein AH, Tucker KL. Centrally located body fat is associated with lower bone mineral density in older Puerto Rican adults. Am J Clin Nutr 2011; 94: 1063–1070.
- 19 Trost SG, McIver KL, Pate RR. Conducting accelerometer-based activity assessments in field-based research. *Med Sci Sports Exerc* 2005; **37**(11 Suppl): 5531–5543.
- 20 Buonani C, Rosa CS, Diniz TA, Christofaro DG, Monteiro HL, Rossi FE et al. [Physical activity and body composition in menopausal women]. *Rev Bras Ginecol Obstet* 2013; 35: 153–158.
- 21 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972; **18**: 499–502.
- 22 Lejskova M, Alusik S, Suchanek M, Zecova S, Pitha J. Menopause: clustering of metabolic syndrome components and population changes in insulin resistance. *Climacteric* 2011; **14**: 83–91.
- 23 Wakayoshi K, Yoshida T, Udo M, Harada T, Moritani T, Mutoh Y et al. Does critical swimming velocity represent exercise intensity at maximal lactate steady state? Eur J Appl Physiol Occup Physiol 1993; 66: 90–95.
- 24 Diniz TA, Fortaleza AC, Rossi FE, Neves LM, Campos EZ, Freitas Junior I. Short-term program of aerobic training prescribed using critical velocity is effective to improve metabolic profile in postmenopausal women. *Sci Sports* 2016; **31**: 95–102.
- 25 da Silva CM, Gurjão ALD, Ferreira L, Gobbi LTB, Gobbi S. Effect of resistance training. prescribed by zone of maximum repetitions on the muscular strength and body composition in older women. *Rev Bras Cineantropom Desempenho Hum* 2006; **8**: 39–45.

- 26 Delshad M, Ghanbarian A, Mehrabi Y, Sarvghadi F, Ebrahim K. Effect of strength training and short-term detraining on muscle mass in women aged over 50 years old. Int J Prev Med 2013; 4: 1386.
- 27 Ratel S, Gryson C, Rance M, Penando S, Bonhomme C, Le Ruyet P et al. Detraininginduced alterations in metabolic and fitness markers after a multicomponent exercise-training program in older men. Appl Physiol Nutr Metab 2011; 37: 72–79.
- 28 Sherk KA, Bemben DA, Brickman SE, Bemben MG. Effects of resistance training duration on muscular strength retention 6-month posttraining in older men and women. J Geriatr Phys Ther 2012; 35: 20–27.
- 29 Vaquero-Cristóbal R, Alacid F, Esparza-Ros F, Muyor JM, López-Miñarro PÁ. Efectos de un programa de 16 semanas de Pilates mat sobre las variables antropométricas y la composición corporal en mujeres adultas activas tras un corto proceso de desentrenamiento. *Nutr Hosp* 2015; **31**: 1738–1747.
- 30 Zhong S, Chen C, Thompson L. Sarcopenia of ageing: functional, structural and biochemical alterations. *Braz J Phys Ther* 2007; **11**: 91–97.
- 31 Bunout D, de la Maza MP, Barrera G, Leiva L, Hirsch S. Association between sarcopenia and mortality in healthy older people. *Australas J Ageing* 2011; 30: 89–92.
- 32 Seifert-Klauss V, Fillenberg S, Schneider H, Luppa P, Mueller D, Kiechle M. Bone loss in premenopausal, perimenopausal and postmenopausal women: results of a prospective observational study over 9 years. *Climacteric* 2012; **15**: 433–440.
- 33 Melnyk JA, Rogers MA, Hurley BF. Effects of strength training and detraining on regional muscle in young and older men and women. *Eur J Appl Physiol* 2009; 105: 929–938.
- 34 Correa CS, Cunha G, Marques N, Oliveira-Reischak A, Pinto R. Effects of strength training, detraining and retraining in muscle strength, hypertrophy and functional tasks in older female adults. *Clin Physiol Funct Imaging* 2015; **36**: 306–310.
- 35 Torres-Leal FL, MD de Capitani, Tirapegui J. The effect of physical exercise and caloric restriction on the components of metabolic syndrome. *Braz J Pharm Sci* 2009; **45**: 379–399.
- 36 Yki-Järvinen H, Koivisto VA. Effects of body composition on insulin sensitivity. *Diabetes* 1983; **32**: 965–969.
- 37 Holloszy J, Hansen P. Regulation of glucose transport into skeletal muscle. *Rev Phys Biochem Pharmacol* 1996; **128**: 99–193.

- 38 Lira FS, Carnevali Jr LC, Zanchi NE, Santos RV, Lavoie JM, Seelaender M. Exercise intensity modulation of hepatic lipid metabolism. J Nutr Metab 2012; 2012: 809576.
- 39 Mittendorfer B, Patterson BW, Klein S. Effect of weight loss on VLDL-triglyceride and apoB-100 kinetics in women with abdominal obesity. Am J Physiol Endocrinol Metab 2003; 284: E549–E556.
- 40 Ghafouri K, Cooney J, Bedford DK, Wilson J, Caslake MJ, Gill JM. Moderate exercise increases affinity of large very low density lipoproteins for hydrolysis by lipoprotein lipase. *J Clin Endocrinol Metab* 2015; **100**: 2205–2213.
- 41 Krauss RM. Dietary and genetic probes of atherogenic dyslipidemia. Arterioscl Thromb Vasc Biol 2005; 25: 2265–2272.
- 42 Riedl I, Yoshioka M, Nishida Y, Tobina T, Paradis R, Shono N et al. Regulation of skeletal muscle transcriptome in elderly men after 6 weeks of endurance training at lactate threshold intensity. Exp Gerontol 2010; 45: 896–903.
- 43 Tikkanen HO, Hamalainen E, Harkonen M. Significance of skeletal muscle properties on fitness, long-term physical training and serum lipids. *Atherosclerosis* 1999; **142**: 367–378.
- 44 Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. *Cardiovasc Ther* 2010; 28: e72–e91.
- 45 Yamamoto K, Takeshita K, Kojima T, Takamatsu J, Saito H. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. *Cardiovasc Res* 2005; 66: 276–285.
- 46 Englund U, Littbrand H, Sondell A, Bucht G, Pettersson U. The beneficial effects of exercise on BMD are lost after cessation: a 5-year follow-up in older postmenopausal women. Scand J Med Sci Sports 2009; 19: 381–388.
- 47 Anjos LA, Barbosa TB, Wahrlich V, Vasconcellos MT. [Patterns of physical activity during a typical day for adults in Niteroi, Rio de Janeiro State, Brazil: the Nutrition, Physical Activity, and Health Survey (PNAFS)]. *Cade Saude Publica* 2012; 28: 1893–1902.
- 48 Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC et al. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. *Med Sci Sports Exerc* 2007; **39**: 1435–1445.

8